CASTLE BIOSCIENCES INC (CSTL)
CASTLE BIOSCIENCES INC (CSTL) from its SEC filings: 2025 revenue $344.2 million (+4% vs the year before), net margin -7%, free cash flow $28.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories |
| Revenue (2025) | $344.2 million |
| Revenue growth | +4% |
| Net income | -$24.2 million |
| Net margin | -7.0% |
| Free cash flow | $28.3 million |
| Diluted EPS | $-0.83 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +20% |
| Cash | $62.1 million |
| Long-term debt | $7.2 million |
| Share count, 1 year | +5% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.